NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection

Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection

Final Report

Drug Class Reviews

, MD, , MPH, , MS, and , MA.

Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director
Portland (OR): Oregon Health & Science University; .

Hepatitis C virus (HCV) is the most common chronic blood borne pathogen in the United States. Chronic HCV infection has a variable course but can cause cirrhosis, liver failure, and hepatocellular cancer after a number of years. Dual therapy with pegylated interferon and ribavirin is now recommended as the antiviral regimen of choice for chronic HCV infection in patients who meet criteria for treatment. However, current guidelines make no recommendation for one pegylated interferon over the other, and it is unclear if there are clinically significant differences between dual therapy with pegylated interferon-alfa 2a versus pegylated interferon-alfa 2b. There is also uncertainty about comparative effectiveness and safety of dual therapy with pegylated interferons in subgroups of patients with HCV (such as those co-infected with HIV infection, those with higher fibrosis stage or higher viral load, those infected with genotype 1, or those who have already failed interferon-based therapy) and in how differences in duration of therapy or dose affect estimates of benefits and harms. The purpose of this review is to compare the benefits and harms of different pharmacologic treatments for chronic hepatitis C infection.

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

Chou R, Carson S, Chan BKS, Care B. Drug Class Review on Pegylated Interferons for Hepatitis C. 2007. http://www.ohsu.edu/drugeffectiveness/reports/final.cfm

The Agency for Healthcare Research and Quality has not yet seen or approved this report.

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2007, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10662PMID: 20496451
PubReader format: click here to try

Views

Other titles in this collection

Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...